Dysregulation of epigenetic related genes in Diabetic Trigger finger Patients; preliminary analysis of Patient-Derived Samples.
Diabetic
Gene expression
Trigger Finger
Journal
Biomolecular concepts
ISSN: 1868-503X
Titre abrégé: Biomol Concepts
Pays: Germany
ID NLM: 101518829
Informations de publication
Date de publication:
31 Dec 2020
31 Dec 2020
Historique:
received:
03
11
2020
accepted:
01
12
2020
entrez:
8
7
2021
pubmed:
9
7
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Trigger finger (TF), a painful condition involving a finger flexor tendon, is a common problem with a prevalence of ~2-3% in the general population. However, the TF prevalence is higher among diabetic patients-ranges from 6.7% to 10%. We have analyzed the expression of the extracellular matrix, inflammation, and epigenetic related genes in diabetic and non-diabetes TF. We hypothesized that Diabetes condition induces alter the expression of epigenetic modification genes in diabetic patients and one of the underlying determinants for more prevalence of TF in diabetic patients. Tissues from the fingers of patients with symptomatic trigger fingers were collected. We had three groups: carpal tunnel syndrome (as a control), trigger finger, and diabetic trigger finger. A quantitative real-time polymerase chain reaction was performed. The gene expression of Extracellular matrix (ECM) components [COL-I, COL-II, COL-X, Aggrecan], DNA methyltransferases enzymes (DNMT1, DNMT3), growth factors (TGF-b, IGF), and Histone deacetylase enzymes (HDAC1, HDAC2) were evaluated in all groups. The mRNA expression of COL-I, COL-II, Aggrecan was significantly higher in the pully A1 of diabetic patients (p= 0.0164, p=0.0351, p=0.0399, respectively) as compared to non-diabetic TF patients. Diabetes was associated with a significant increase in the DNMT3 expression compared to non-diabetic TF patients (p=0.0485). HDAC1 and HDAC2 gene expression were up-regulated in diabetic TF than non-diabetic TF. The chronic state of hyperglycemia induces epigenetic modification of gene expressions in trigger fingers. This seems to have a significant impact on the development, recurrence, and progression of trigger finger in diabetic patients.
Sections du résumé
BACKGROUND
BACKGROUND
Trigger finger (TF), a painful condition involving a finger flexor tendon, is a common problem with a prevalence of ~2-3% in the general population. However, the TF prevalence is higher among diabetic patients-ranges from 6.7% to 10%. We have analyzed the expression of the extracellular matrix, inflammation, and epigenetic related genes in diabetic and non-diabetes TF. We hypothesized that Diabetes condition induces alter the expression of epigenetic modification genes in diabetic patients and one of the underlying determinants for more prevalence of TF in diabetic patients.
METHOD
METHODS
Tissues from the fingers of patients with symptomatic trigger fingers were collected. We had three groups: carpal tunnel syndrome (as a control), trigger finger, and diabetic trigger finger. A quantitative real-time polymerase chain reaction was performed. The gene expression of Extracellular matrix (ECM) components [COL-I, COL-II, COL-X, Aggrecan], DNA methyltransferases enzymes (DNMT1, DNMT3), growth factors (TGF-b, IGF), and Histone deacetylase enzymes (HDAC1, HDAC2) were evaluated in all groups.
RESULTS
RESULTS
The mRNA expression of COL-I, COL-II, Aggrecan was significantly higher in the pully A1 of diabetic patients (p= 0.0164, p=0.0351, p=0.0399, respectively) as compared to non-diabetic TF patients. Diabetes was associated with a significant increase in the DNMT3 expression compared to non-diabetic TF patients (p=0.0485). HDAC1 and HDAC2 gene expression were up-regulated in diabetic TF than non-diabetic TF.
CONCLUSION
CONCLUSIONS
The chronic state of hyperglycemia induces epigenetic modification of gene expressions in trigger fingers. This seems to have a significant impact on the development, recurrence, and progression of trigger finger in diabetic patients.
Identifiants
pubmed: 34233433
pii: bmc-2020-0020
doi: 10.1515/bmc-2020-0020
doi:
Substances chimiques
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
221-229Informations de copyright
© 2020 Michael Cain et al., published by De Gruyter.
Références
Moore JS. Flexor tendon entrapment of the digits (trigger finger and trigger thumb). J Occup Environ Med. 2000 May;42(5):526–45.
Ryzewicz M, Wolf JM. Trigger digits: principles, management, and complications. J Hand Surg Am. 2006 Jan;31(1):135–46.
Lundin AC, Eliasson P, Aspenberg P. Trigger finger and tendinosis. J Hand Surg Eur Vol. 2012 Mar;37(3):233–6.
McAuliffe JA. Tendon disorders of the hand and wrist. J Hand Surg Am. 2010 May;35(5):846–53.
Bonnici AV, Spencer JD. A survey of ‘trigger finger’ in adults. J Hand Surg [Br]. 1988 May;13(2):202–3.
Weilby A. Trigger finger. Incidence in children and adults and the possibility of a predisposition in certain age groups. Acta Orthop Scand. 1970;41(4):419–27.
Peters-Veluthamaningal C, van der Windt DA, Winters JC, Meyboom-de Jong B. Corticosteroid injection for trigger finger in adults. Cochrane Database Syst Rev. 2009 Jan;(1):CD005617.
Wessel LE, Fufa DT, Boyer MI, Calfee RP. Epidemiology of carpal tunnel syndrome in patients with single versus multiple trigger digits. J Hand Surg Am. 2013 Jan;38(1):49–55.
Stahl S, Kanter Y, Karnielli E. Outcome of trigger finger treatment in diabetes. J Diabetes Complications. 1997 Sep-Oct;11(5):287–90.
Grandizio LC, Beck JD, Rutter MR, Graham J, Klena JC. The incidence of trigger digit after carpal tunnel release in diabetic and nondiabetic patients. J Hand Surg Am. 2014 Feb;39(2):280– 5.
Douloumpakas I, Pyrpasopoulou A, Triantafyllou A, Sampanis C, Aslanidis S. Prevalence of musculoskeletal disorders in patients with type 2 diabetes mellitus: a pilot study. Hippokratia. 2007 Oct;11(4):216–8.
Abate M, Schiavone C, Salini V, Andia I. Occurrence of tendon pathologies in metabolic disorders. Rheumatology (Oxford). 2013 Apr;52(4):599–608.
Anderson B, Kaye S. Treatment of flexor tenosynovitis of the hand (‘trigger finger’) with corticosteroids. A prospective study of the response to local injection. Arch Intern Med. 1991 Jan;151(1):153–6.
Benson LS, Ptaszek AJ. Injection versus surgery in the treatment of trigger finger. J Hand Surg Am. 1997 Jan;22(1):138–44.
Murphy D, Failla JM, Koniuch MP. Steroid versus placebo injection for trigger finger. J Hand Surg Am. 1995 Jul;20(4):628– 31.
Zyluk A, Jagielski G. Percutaneous A1 pulley release vs steroid injection for trigger digit: the results of a prospective, randomized trial. J Hand Surg Eur Vol. 2011 Jan;36(1):53–6.
Mol MF, Neuhaus V, Becker SJ, Jupiter JB, Mudgal C, Ring D. Resolution and recurrence rates of idiopathic trigger finger after corticosteroid injection. Hand (N Y). 2013 Jun;8(2):183–90.
Grandizio LC, Speeckaert A, Brothers J, Graham J, Klena JC. Predictors of Recurrence After Corticosteroid Injection for Trigger Digits. Hand (N Y). 2017 Jul;12(4):352–6.
Rorbach-Dolata A, Kubis A, Piwowar A. Epigenetic modifications: an important mechanism in diabetic disturbances. Postepy Hig Med Dosw. 2017 Nov;71(0):960–74.
Bayarsaihan D. Epigenetic mechanisms in inflammation. J Dent Res. 2011 Jan;90(1):9–17.
Lundin AC, Aspenberg P, Eliasson P. Trigger finger, tendinosis, and intratendinous gene expression. Scand J Med Sci Sports. 2014 Apr;24(2):363–8.
Corps AN, Robinson AH, Movin T, Costa ML, Hazleman BL, Riley GP. Increased expression of aggrecan and biglycan mRNA in Achilles tendinopathy. Rheumatology (Oxford). 2006 Mar;45(3):291–4.
de Mos M, van El B, DeGroot J, Jahr H, van Schie HT, van Arkel ER, et al. Achilles tendinosis: changes in biochemical composition and collagen turnover rate. Am J Sports Med. 2007 Sep;35(9):1549–56.
Ireland D, Harrall R, Curry V, Holloway G, Hackney R, Hazleman B, et al. Multiple changes in gene expression in chronic human Achilles tendinopathy. Matrix Biol. 2001 Jun;20(3):159–69.
Eriksen HA, Pajala A, Leppilahti J, Risteli J. Increased content of type III collagen at the rupture site of human Achilles tendon. J Orthop Res. 2002 Nov;20(6):1352–7.
Kannus P. Structure of the tendon connective tissue. Scand J Med Sci Sports. 2000 Dec;10(6):312–20.
Benjamin, M. and J.R. Ralphs, Fibrocartilage in tendons and ligaments — an adaptation to compressive load. 1998. 193(Pt 4): p. 481-94.
Robbins JR, Evanko SP, Vogel KG. Mechanical loading and TGF-beta regulate proteoglycan synthesis in tendon. Arch Biochem Biophys. 1997 Jun;342(2):203–11.
Thomopoulos S, Williams GR, Gimbel JA, Favata M, Soslowsky LJ. Variation of biomechanical, structural, and compositional properties along the tendon to bone insertion site. J Orthop Res. 2003 May;21(3):413–9.
Studentsova V, et al. Obesity/Type II Diabetes Promotes Function-Limiting Changes In Flexor Tendon Extracellular Matrix Organization That Are Not Reversed By Restoring Normal Metabolic Function. bioRxiv, 2017: p. 143149.
Wei AS, Callaci JJ, Juknelis D, Marra G, Tonino P, Freedman KB, et al. The effect of corticosteroid on collagen expression in injured rotator cuff tendon. J Bone Joint Surg Am. 2006 Jun;88(6):1331– 8.
Nathan C, Sporn M. Cytokines in context. J Cell Biol. 1991 Jun;113(5):981–6.
Turley JM, Falk LA, Ruscetti FW, Kasper JJ, Francomano T, Fu T, et al. Transforming growth factor beta 1 functions in monocytic differentiation of hematopoietic cells through autocrine and paracrine mechanisms. Cell Growth Differ. 1996 Nov;7(11):1535– 44.
Yang L, Qiu CX, Ludlow A, Ferguson MW, Brunner G. Active transforming growth factor-beta in wound repair: determination using a new assay. Am J Pathol. 1999 Jan;154(1):105–11.
S., J., et al., Transforming growth factor‐β1 and fibroblast growth factors in rat growth plate. Journal of Orthopaedic Research, 1995. 13(5): p. 761-768.
Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature. 1992 Nov;360(6402):361–4.
Westergren-Thorsson G, Hernnäs J, Särnstrand B, Oldberg A, Heinegård D, Malmström A. Altered expression of small proteoglycans, collagen, and transforming growth factor-beta 1 in developing bleomycin-induced pulmonary fibrosis in rats. J Clin Invest. 1993 Aug;92(2):632–7.
Bakker AC, van de Loo FA, van Beuningen HM, Sime P, van Lent PL, van der Kraan PM, et al. Overexpression of active TGF-beta-1 in the murine knee joint: evidence for synovial-layer-dependent chondro-osteophyte formation. Osteoarthritis Cartilage. 2001 Feb;9(2):128–36.
Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol. 2010 Oct;28(10):1069–78.
Fernández MP, Young MF, Sobel ME. Methylation of type II and type I collagen genes in differentiated and dedifferentiated chondrocytes. J Biol Chem. 1985 Feb;260(4):2374–8.
Gabay O, Clouse KA. Epigenetics of cartilage diseases. Joint Bone Spine. 2016 Oct;83(5):491–4.
Yan, J., et al., diabetes impairs wound healing by Dnmt1-dependent dysregulation of hematopoietic stem cells differentiation towards macrophages. Nature Communications, 2018. 9(1): p. 33. 43.
Mishra M, Kowluru RA. The role of DNA methylation in the metabolic memory phenomenon associated with the continued progression of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2016 Oct;57(13):5748–57.
Guo K, Eid SA, Elzinga SE, Pacut C, Feldman EL, Hur J. Genome-wide profiling of DNA methylation and gene expression identifies candidate genes for human diabetic neuropathy. Clin Epigenetics. 2020 Aug;12(1):123.
Zhang L, Zhang Q, Liu S, Chen Y, Li R, Lin T, et al. DNA methyltransferase 1 may be a therapy target for attenuating diabetic nephropathy and podocyte injury. Kidney Int. 2017 Jul;92(1):140–53.
Delcuve GP, Khan DH, Davie JR. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics. 2012 Mar;4(1):5.
Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H, et al. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am J Physiol Renal Physiol. 2009 Sep;297(3):F729–39.
Lee HA, Lee E, Do GY, Moon EK, Quan FS, Kim I. Histone deacetylase inhibitor MGCD0103 protects the pancreas from streptozotocin-induced oxidative stress and β-cell death. Biomed Pharmacother. 2019 Jan;109:921–9.
Ganesan A, Arimondo PB, Rots MG, Jeronimo C, Berdasco M. The timeline of epigenetic drug discovery: from reality to dreams. Clin Epigenetics. 2019 Dec;11(1):174.
Martinez-Moreno JM, Fontecha-Barriuso M, Martin-Sanchez D, Guerrero-Mauvecin J, Goma-Garces E, Fernandez-Fernandez B, et al. Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease. Int J Mol Sci. 2020 Jun;21(11):4113.
Martinez-Moreno JM, Fontecha-Barriuso M, Martin-Sanchez D, Guerrero-Mauvecin J, Goma-Garces E, Fernandez-Fernandez B, et al. Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease. Int J Mol Sci. 2020 Jun;21(11):4113.
Arguelles AO, Meruvu S, Bowman JD, Choudhury M. Are epigenetic drugs for diabetes and obesity at our door step? Drug Discov Today. 2016 Mar;21(3):499–509.